{
    "clinical_study": {
        "@rank": "104342", 
        "arm_group": [
            {
                "arm_group_label": "CT-P13", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "CT-P13, switch to Remicade", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Remicade", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Remicade, switch to CT-P13", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to assess noninferiority in efficacy and to assess overall safety of CT P13\n      compared to Remicade in patients with active Crohn's disease up to Week 54."
        }, 
        "brief_title": "Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Crohn's Disease", 
        "condition_browse": {
            "mesh_term": "Crohn Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients with active Crohn's disease and a Crohn's disease activity\n             index score between 220 and 450 points\n\n        Exclusion Criteria:\n\n          -  Patient who has previously received a biological agent for the treatment of Crohn's\n             disease.\n\n          -  Patient who has allergies to any of the excipients of infliximab, any other murine\n             and/or human proteins, or patient with a hypersensitivity to immunoglobulin product."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "214", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096861", 
            "org_study_id": "CT-P13 3.4", 
            "secondary_id": "2013-004497-10"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "CT-P13", 
                    "CT-P13, switch to Remicade", 
                    "Remicade, switch to CT-P13"
                ], 
                "description": "CT-P13 (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose", 
                "intervention_name": "CT-P13", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "CT-P13, switch to Remicade", 
                    "Remicade", 
                    "Remicade, switch to CT-P13"
                ], 
                "description": "Remicade (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose", 
                "intervention_name": "Remicade", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Infliximab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 24, 2014", 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 Compared to Remicade in Patients With Active Crohn's Disease", 
        "overall_contact": {
            "email": "BoYoung.Choi@celltrion.com", 
            "last_name": "BoYoung Choi"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Korea: Ministry of Food and Drug Safety", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Efficacy evaluated by Assessment of Crohn's disease activity index  -70 response", 
            "safety_issue": "No", 
            "time_frame": "at Week 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096861"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Celltrion", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celltrion", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}